Holen Sie sich die Stockscreener-App
5.80
0.09%
0.010
Schlusskurs vom Vortag:
$5.79
Offen:
$5.8
24-Stunden-Volumen:
245.14K
Relative Volume:
0.26
Marktkapitalisierung:
$219.70M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
-2.2568
EPS:
-2.57
Netto-Cashflow:
$-67.42M
1W Leistung:
+0.43%
1M Leistung:
+1.49%
6M Leistung:
+0.09%
1J Leistung:
-58.31%
1-Tages-Spanne:
$5.79
$5.805
1-Wochen-Bereich:
$5.73
$5.82
52-Wochen-Spanne:
$3.165
$14.70
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
5.79 | 219.70M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
126.15 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.93 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.31 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.10 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.64 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
StockNews.com Initiates Coverage on Nevro (NYSE:NVRO) - MarketBeat
SEC Form DEFM14A filed by Nevro Corp. - Quantisnow
StockNews.com Begins Coverage on Nevro (NYSE:NVRO) - MarketBeat
Nevro (NYSE:NVRO) Announces Earnings Results - MarketBeat
Nevro Corp. to Host Earnings Call - ACCESS Newswire
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Reduce" by Analysts - MarketBeat
(NVRO) Investment Report - Stock Traders Daily
Nevro Corp. (NYSE:NVRO) Short Interest Update - MarketBeat
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down - Yahoo Finance
Nevro revenue drops 9.1% to USD 105.5M in Q4 2024 - Medical Buyer
Nevro: Q4 Earnings Snapshot - Midland Daily News
Nevro Corp. Reports 2024 Financial Results Amid Acquisition News - TipRanks
Nevro Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results - The Malaysian Reserve
Nevro Corp earnings missed by $0.63, revenue topped estimates - Investing.com Canada
Nevro: Q4 Earnings Snapshot -March 04, 2025 at 04:56 pm EST - Marketscreener.com
Nevro reports Q4 revenue beat, but wider loss than expected By Investing.com - Investing.com South Africa
Nevro reports Q4 revenue beat, but wider loss than expected - Investing.com India
Nevro Corp (NVRO) Q4 2024 Earnings Report Preview: What To Expec - GuruFocus.com
Nevro Corp (NVRO) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Globus Medical to Acquire Nevro in $250 Million Deal - The Healthcare Technology Report.
Nevro (NYSE:NVRO) Now Covered by Analysts at StockNews.com - MarketBeat
Globus Medical to acquire Nevro for $5.85 per share - MSN
Investor Network: Nevro Corp. to Host Earnings Call - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Siyata Mobile Inc. (NasdaqSYTA), Bridge Investment Group Holdings Inc. (NYSEBRDG), Nevro Corp. (NYSE – NVRO), 180 Degree Capital Corp. (Nasdaq - TradingView
The Real Story Behind Globus’s Nevro Deal - https://ryortho.com/
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NVRO, LGTY, AVTE, PLYA - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PLYA, NVRO on Behalf of Shareholders - Marketscreener.com
Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders - Kilgore News Herald
Nevro (NYSE:NVRO) Now Covered by StockNews.com - MarketBeat
Globus Medical beats Street in Q4, stock dips as analysts question Nevro buy - Mass Device
Earnings call transcript: Globus Medical Q4 2024 earnings beat forecasts, shares dip - Investing.com UK
Globus Medical’s $250 Million Acquisition of Nevro Corp. - Global Legal Chronicle
Globus Medical's SWOT analysis: stock outlook amid acquisition and FDA warning - MSN
Globus Medical Pays 38% Premium for Nevro - https://ryortho.com/
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal - MSN
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):